About RS Research
This author has not written his bio yet.
But we are proud to say that RS Research contributed 65 entries already.
Entries by RS Research
RS Research announces that the phase 1 study of RS-0139 is now part of the ESMO Congress 2026 scientific programme
The phase 1 study of RS-0139 is now part of the ESMO Congress 2026 scientific programme, to be held in Madrid at 23-27 October 2026:
“First-in-human phase Ia/Ib study of RS-0139, an integrin-targeted docetaxel prodrug, in advanced solid tumors”
HURRIYET DAILY NEWS
First homegrown cancer drug clears phase 1 trials
MILLIYET
A historic milestone in cancer drug development
RS Research announces successful completion of phase 1 clinical trial of RS-0139 in solid tumors
RS Research, a biotechnology company developing smart nanomedicines for oncology, has announced the successful completion of the Phase 1 clinical trial of its lead investigational candidate, RS-0139, in patients with solid tumors. […]
FORBES
Cover Story – The Business Leaders of Science: Smart fight against cancer
RS Research announces online abstract acceptance at the 2025 ASCO Annual Meeting
RS Research, a clinically-validated biotechnology company developing targeted oncology therapies with a focus on improved safety and efficacy, announced that an abstract presenting the Phase 1a clinical trial results of its lead candidate, RS_0139, has been accepted for online publication at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL. […]
EIC
Prof. Rana Sanyal won the European Prize for Women Innovators
FORBES
RS Research was listed in among the most successful startups in Forbes’ 2025 Startup 50!
RS Research is a clinically-validated biotech company developing targeted oncology therapies using Sagitta® drug-delivery platforms, disrupting the efficacy-toxicity trade-off.
